SAS unveils AI agents with customizable human-AI interaction for transparent decisioning
ORLANDO, Fla., May 7, 2025 /PRNewswire/ -- SAS INNOVATE -- Imagine a future where AI systems render decisions and take action with little to no human intervention. With the rapid advance of AI agents that future is nearly here. That's why SAS is building the agentic AI future on its bedrock of responsible innovation. SAS® Intelligent Decisioning – available on industry-leading data and AI platform SAS® Viya® – empowers organizations to design, deploy and scale AI agents with balanced human and AI autonomy, embedded governance and explainability of decisions.
"SAS' approach to agentic AI strikes the critical balance between autonomous decision-making and ethical governance," said Nick Patience, Vice President and Practice Lead, Artificial Intelligence Software and Tools at The Futurum Group. "Its intelligent agents represent not just technological advancement but a pragmatic framework for responsible enterprise AI adoption – precisely what organizations need as they navigate this rapidly evolving landscape to gain a competitive advantage."
AI agents get decisioning support with ethical calibration
True enterprise value from agentic AI comes from building collaborative, intelligence-amplifying systems that work with humans. SAS Viya's agentic AI framework is underpinned by three pillars that define how AI agents are designed and delivered:
Decisioning. Applying a hybrid approach that combines the rigor of powerful deterministic analytics with the flexibility and reasoning of large language models (LLMs) enables customers to build AI agents that deliver precise and reliable outcomes, with the necessary business guardrails and rules required in regulated industries.
Human and AI balance. SAS enables organizations to determine the appropriate level of AI autonomy and human involvement for AI agents based on task complexity, risk, and business goals. AI agents can operate fully autonomously in routine, data-driven tasks while humans provide oversight, ethical judgment, and strategic direction.
Governance. SAS' built-in governance framework enables customers to build AI agents that not only deliver accurate outcomes but also adhere to ethical standards, maintain data privacy, align with business values and stand up to regulatory scrutiny.
"As organizations evolve toward open, interoperable AI ecosystems across multi-cloud and hybrid environments, trust and explainability in AI governance are emerging as key differentiators among tech vendors," said Tiffany McCormick, Research Director, Digital Business Models and Monetization at IDC. "SAS is taking industry-leading steps to address the growing demand for agentic AI, with a clear commitment to ethical rigor and differentiated execution in AI decisioning."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Personify Unveils WildApricot.com Redesign to Accelerate Growth for Member Organizations
AUSTIN, Texas, July 2, 2025 /PRNewswire/ -- Personify, Inc. ("Personify") today announced the launch of a redesigned digital experience for the #1 membership management software for small associations, nonprofits and clubs. The new site offers faster navigation, a more intuitive layout, and expanded resources to help mission-driven organizations explore and adopt the tools they need to grow. "This wasn't just a design update. It was a response to what WildApricot users told us they needed," said Erin Sullivan, Vice President of Marketing at Personify. "From an intuitive and modern design to a simplified free trial process and more robust educational resources, everything about the new site reflects what today's association, nonprofit and club professionals are looking for when shopping for member management software." Redesigned with Users in Mind The new makes it easier for associations, clubs and nonprofits to find and implement the right tools for growth. Here's what's new and improved: A clean, modern design for a trusted brand that feels current and credible Smarter navigation that helps visitors find what they're looking for faster Tailored calls to action based on whether visitors are exploring, evaluating or ready to start Real product visuals so visitors know exactly what to expect A new mascot, Sunny, brings personality to the site and helps guide users through the experience The redesign also introduces more robust educational support. Resources That Help Organizations Grow Whether someone is brand new or ready to dive deeper, the updated site makes it easier to access WildApricot's learning and support tools. Helpful highlights include: A 60-day free trial that comes with personalized coaching A Help Center with over 900 how-to guides and tutorials An industry-leading education hub packed with blog posts, webinars and best practices Live boot camps for step-by-step onboarding and setup help The goal is to reduce guesswork, build confidence and help organizations get value quickly, starting from their very first visit. "WildApricot has helped more than 15,000 organizations streamline operations and grow their communities," Sullivan added. "This redesign honors that legacy and makes it easier for the next 15,000 to get started." Experience It Firsthand Ready to see it in action? Visit the new to meet Sunny and explore the powerful tools trusted by 15,000+ organizations. For more information, visit About Personify and WildApricot Personify partners with associations, chambers of commerce, nonprofits, YMCAs, JCCs and other mission-driven organizations to bring people and ideas together. Its technology platform and service offerings empower clients to build strong revenue streams, deepen engagement, and achieve long-term success. WildApricot is the #1 membership management software for small associations, nonprofits and clubs. With intuitive tools for managing memberships, events, websites, and more, WildApricot helps organizations grow and connect with their communities. View original content to download multimedia: SOURCE Personify Corp Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Muon Space Releases First Light Images from FireSat Protoflight
Advanced multispectral infrared payload demonstrates exceptional capabilities in inaugural on-orbit demonstration MOUNTAIN VIEW, Calif., June 26, 2025 /PRNewswire/ -- Muon Space, a leading provider of end-to-end space systems specializing in mission-optimized satellite constellations, today released the first light images from its FireSat Protoflight, marking a significant milestone in the development of the world's first dedicated wildfire detection and monitoring constellation. The images, captured by Muon's state-of-the-art six-channel multispectral infrared (IR) instrument, demonstrate the exceptional capabilities of this revolutionary IR technology for detecting and monitoring thermal activities. Launched on March 14th aboard SpaceX's Transporter-13 mission, the FireSat constellation is a collaboration between Muon and the nonprofit Earth Fire Alliance to enhance global wildfire response by delivering actionable data to first responders, policymakers, and communities facing escalating wildfire threats. The satellite's six-channel multispectral IR instrument – designed and built in-house – places Muon among a select group of commercial companies capable of developing and operating advanced space-based thermal sensors. Capturing IR imagery validates both the instrument and Muon's vertically integrated satellite platform. "The FireSat first light images demonstrate Muon's approach to building mission-optimized satellites including purpose-built instruments," said Jonny Dyer, CEO of Muon Space. "I'm ecstatic with both the speed at which we moved from FireSat mission formulation to an orbit demonstration and the quality of the data that we are now collecting." Captured in June 2025 using FireSat Protoflight's multispectral infrared sensors, our first imagery set reveals urban heat islands, airport runway activity, and water temperature variations in Sydney, Australia; lava fountains at Hawaii's Kīlauea volcano; and gas flares at Libya's Sarir oil field complex. "These first light images confirm that our IR sensors are operating as designed and collecting high-quality data," said Dan McCleese, Chief Scientist of Muon Space. "Infrared imaging with this quality is one of the most technically demanding domains in remote sensing, and we're proud to be among the few commercial players advancing this capability in orbit." A New Layer of Intelligence for Wildfire Detection, Tracking, and Response FireSat is capable of multispectral imaging across the visible, near-infrared, short-, mid- and long-wave infrared bands simultaneously. High-fidelity IR data is essential for detecting wildfires in their early stages, monitoring fire dynamics, and tracking other thermal anomalies. FireSat addresses a longstanding gap in space-based wildfire monitoring by delivering persistent, high-resolution, actionable intelligence to government and commercial users. Distinguished by its high-dynamic range (HDR) multispectral IR instrument, the FireSat Constellation is uniquely equipped to differentiate genuine wildfire events from false positives and enhance the accuracy and reliability of wildfire detection and assessment of fire intensity. The FireSat constellation will operate in LEO with an observation swath width of 1,500 km and an nadir ground sample distance of 50m. The instrument's resolution, sensitivity and large dynamic range enable it to detect small cool fires 5x5 meters while also imaging without saturation for hot intense fires. As the demonstration mission for a planned 50+ satellite constellation, FireSat Protoflight will soon begin providing high-resolution thermal infrared data to meet growing demand across government, commercial, and environmental sectors. The full constellation will deliver global coverage, with each point on Earth observed every 20 minutes and key wildfire-prone regions benefiting from more frequent observations. The FireSat initiative is led by the Earth Fire Alliance and supported by Google Research, along with leading NGOs and philanthropic organizations including the Gordon and Betty Moore Foundation, and the Environmental Defense Fund. This milestone builds on Muon's earlier announcement that FireSat was successfully deployed and communicating in orbit. The company remains on track to launch the first block of three additional FireSat satellites in 2026, with full operational FireSat constellation capacity targeted for 2030. About Muon Space Founded in 2021, Muon Space is an end-to-end space systems company that designs, builds, and operates mission-optimized satellite constellations to deliver critical data and enable real-time compute and decision-making in space. Its proprietary technology stack, Halo™, integrates advanced spacecraft platforms, robust payload integration and management, and a powerful software-defined orchestration layer to enable high-performance capabilities at unprecedented speed – from concept to orbit. With state-of-the-art production facilities in Silicon Valley and a growing track record of national security and commercial customers, Muon Space is redefining how critical Earth intelligence is delivered from space. For more information on Muon Space, visit: About Earth Fire Alliance Earth Fire Alliance is a California Nonprofit Public Benefit Corporation founded in 2024 on the belief that high-fidelity data, accessible on a global scale, will transform humanity's collective approach and relationship to fire. The Alliance shares a vision of expanding wildfire focus and funding from reactive suppression to proactive stewardship that includes better informed real-time decisions on the ground, data-driven resilience initiatives, and improved understanding about the positive and negative role of fire on the landscape. Committed to delivering transformative real-time data from all wildfires on Earth through user-driven technology and radical collaboration, Earth Fire Alliance champions the FireSat satellite constellation. FireSat will deliver unprecedented data about where fires are and how fast they're moving to frontline fire responders around the globe. Learn more about the Alliance, FireSat, and how to get involved or support at View original content to download multimedia: SOURCE Muon Space Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
an hour ago
- Associated Press
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
HYOGO, Japan--(BUSINESS WIRE)--Jul 2, 2025-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141 (INN: pabinafusp alfa), which is in development for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome). The Phase III clinical trial is ongoing in the United States, Latin America, and Europe. ( JR-141-GS31 ) JR-141 is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in people with Hunter syndrome. JR-141 was developed using J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, which is designed to deliver biotherapeutics across the BBB into the central nervous system (CNS) to address the neurological symptoms of Hunter syndrome. 'This achievement is a milestone in the JR-141 clinical development program, as the Hunter syndrome community needs a therapy that treats the cognitive symptoms of this devastating and life-threatening disease for which there are inadequate treatment options available,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are making good progress in this global Phase III clinical trial, and we look forward to sharing the clinical data as they are available. Thank you to all the participants who are part of this clinical trial.' In March 2021, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved JR-141 (also known by the brand name IZCARGO ® ) for a lysosomal storage disorder. JR-141 is the first-ever approved ERT in the world that penetrates the BBB. About JR-141 JR-141 (INN: pabinafusp alfa) is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in subjects with Hunter syndrome. It incorporates J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, to cross the BBB through transferrin receptor-mediated transcytosis, and its uptake into cells is mediated through the mannose-6-phosphate receptor. This novel mechanism of action is expected to make JR-141 effective against the central nervous system (CNS) symptoms of Hunter syndrome. In non-clinical trials, JCR has confirmed both high-affinity binding of pabinafusp alfa to transferrin receptors and passage across the BBB into neuronal cells. In addition, JCR has confirmed enzyme uptake in various brain tissues. The company has also confirmed a reduction of substrate accumulation in the CNS and peripheral organs in an animal model of Hunter syndrome. 1,2 In several clinical trials of pabinafusp alfa, JCR obtained evidence of reducing heparan sulfate concentrations in the cerebrospinal fluid, a biomarker for assessing effectiveness against CNS symptoms; these results were consistent with those obtained in pre-clinical studies. 3 Clinical studies have also demonstrated the positive effects of pabinafusp alfa on CNS symptoms. 4,5,6 About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future. 2: Morimoto, et al. Clearance of heparin sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol. Ther. 2021; 29(5): 1853-1861. 3: Okuyama, et al. Iduronate-2-sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Mol Ther. 2020; 27(2): 456-464. 4: Okuyama, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther. 2021; 29(2): 671-679. 5: Giugliani, et al. Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: Report of a phase 2 trial in Brazil. Mol Ther. 2021; 29(7): 2378-2386. 6: Giugliani, et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II; an Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938. View source version on CONTACT: Investors & Media: JCR Pharmaceuticals Co., Ltd. Corporate Communications [email protected] KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: RESEARCH NEUROLOGY CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE SOURCE: JCR Pharmaceuticals Co., Ltd. Copyright Business Wire 2025. PUB: 07/02/2025 11:12 AM/DISC: 07/02/2025 11:12 AM
